IBZM

IBZM

IBZM (Iodobenzamide) is a radioligand used in nuclear medicine and neuroimaging to visualize and study the dopamine receptor D2/D3 in the brain. It is a non-invasive method that allows for the in vivo examination of the dopaminergic system.

History

IBZM was first synthesized in the 1980s as a tool for the study of the dopaminergic system. It was developed as a radiotracer for Single-photon emission computed tomography (SPECT) imaging.

Mechanism of Action

IBZM binds selectively to the D2/D3 dopamine receptors in the brain. It is a competitive antagonist, meaning it competes with dopamine for the same binding site. This allows for the visualization of the distribution and density of these receptors in the brain.

Applications

IBZM SPECT is used in the diagnosis and monitoring of various neurological disorders, including Parkinson's disease, schizophrenia, and drug addiction. It can also be used in research to study the effects of drugs on the dopaminergic system.

Procedure

The procedure for an IBZM SPECT scan involves the intravenous injection of the radioligand, followed by a waiting period to allow for the radioligand to distribute in the brain. The patient is then placed in the SPECT scanner, and images are taken over a period of time.

Safety and Side Effects

As with any medical procedure, there are potential risks and side effects associated with IBZM SPECT. These can include allergic reactions to the radioligand, as well as the potential for radiation exposure. However, the benefits of the procedure generally outweigh these risks.

See Also

• Radioligand
• Dopamine receptor
• Single-photon emission computed tomography